QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

KROS

QT47Keros Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
10.65
+0.24+2.31%
OverviewShort InterestFilings
KROSQT47Keros Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
10.65+2.31%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
1.54
Insider Own-
Shs Outstand19.79M
Perf Week5.97%
Market Cap333.10MForward P/E-EPS next Y-5.41Insider Trans0.44%Shs Float-Perf Month7.47%
Enterprise Value67.91MPEG0.00EPS next Q-1.20Inst Own-Short Float-Perf Quarter-4.23%
Income-73182052.00P/S10.04EPS this Y-478.20%Inst Trans-Short Ratio-Perf Half Y-50.53%
Sales33.18MP/B1.36EPS next Y7.14%ROA-27.26%Short Interest-Perf YTD-47.69%
Book/sh14.45P/C-EPS next 5Y-ROE-17.04%52W High22.55 -52.77%Perf Year-20.88%
Cash/sh14.20P/FCF-EPS past 3/5Y-ROIC-34.46%52W Low9.69 9.91%Perf 3Y-
Dividend Est.-EV/EBITDA-0.77Sales past 3/5Y-Gross Margin96.48%Volatility2.90% 3.10%Perf 5Y-
Dividend TTM-EV/Sales2.05EPS Y/Y TTM39.80%Oper. Margin-332.55%ATR (14)0.51Perf 10Y-
Dividend Ex-Date-Quick Ratio22.62Sales Y/Y TTM6050.00%Profit Margin-256.60%RSI (14)49.80Recom2.44
Dividend Gr. 3/5Y-Current Ratio22.62EPS Q/Q-133.43%SMA200.41%Beta1.21Target Price102.60
Payout0.00%Debt/Eq0.06Sales Q/Q-100.00%SMA50-3.95%Rel Volume1.33Prev Close10.41
Employees163LT Debt/Eq0.05EarningsAug 05SMA200-28.86%Avg Volume301.39KPrice10.65
IPO DateApr 08, 2020Option/ShortYes / YesEPS/Sales Surpr.-31.52% -100.00%Net Debt/EBITDA2.99Volume400,525Change2.31%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-25DowngradeB of A SecuritiesBuy → Neutral
Jan-21-25DowngradeCantor FitzgeraldOverweight → Neutral
Jan-17-25DowngradeWedbushOutperform → Neutral
Dec-16-24DowngradeGuggenheimBuy → Neutral
Dec-12-24DowngradeTD CowenBuy → Hold
Dec-12-24DowngradeWilliam BlairOutperform → Market Perform
Dec-12-24DowngradeBTIGBuy → Neutral
Nov-05-24ReiteratedJefferiesBuy$107
Nov-05-24ReiteratedTruist Financial$100
Sep-23-24ReiteratedGuggenheim$96
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2462444
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A020
Gross Profit2462434
Selling, General and Administrative Excl. Other454741
Research and Development159130174
Other Operating Expense-2-5-1
Operating Income4471-211
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-44-21-24
Net Income Before Taxes7092-187
Income Taxes750
Consolidated Net Income6487-187
Net Income From Continuing Operations6487-187
Net Income6487-187
EPS (Recurring)1.582.34-5.00
EPS (Basic, Before Extraordinaries)1.582.34-5.00
EPS (Diluted)1.542.30-5.00
EBITDA8993-186
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio6.928.85—
Price To Sales Ratio1.783.09—
Gross Margin100.0099.59100.00
Operating Margin17.8929.10-5,275.00
Net Margin26.0235.66-4,675.00
Shares Outstanding413737
Market Capitalization437753—
Operating Lease Expense
———
Insider Trading Volume
$11.21$10.00$8.79$7.58$6.37● Close Price0.00M3.99M7.98M11.96M15.95MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BIENAIME JEAN JACQUESDirectorJun 15 '26Buy10.191,00010,19017,592Jun 17 12:00 AM
Newton Charles W.DirectorJun 11 '26Sale10.045505,52212,665Jun 15 12:00 AM
Farzan NimaDirectorJun 04 '26Sale10.732,62528,1669,767Jun 08 12:00 AM
Knowles JuliusDirectorJun 04 '26Sale10.732,62528,16610,958Jun 08 12:00 AM
Seth AlpnaDirectorJun 04 '26Sale10.722,62528,1409,767Jun 05 12:00 AM
BIENAIME JEAN JACQUESDirectorMay 15 '26Buy10.581,00010,5809,450May 19 12:00 AM
BIENAIME JEAN JACQUESDirectorApr 15 '26Buy11.701,00011,7008,450Apr 17 12:00 AM
Seehra JasbirCHIEF EXECUTIVE OFFICERApr 02 '26Option Exercise0.30110,00033,000440,708Apr 06 12:00 AM
BIENAIME JEAN JACQUESDirectorMar 09 '26Buy11.212,00022,4207,450Mar 11 12:00 AM
Seehra JasbirCHIEF EXECUTIVE OFFICERFeb 19 '26Sale16.177,015113,433385,708Feb 20 12:00 AM
Lerner Lorena RaquelChief Science OfficerFeb 18 '26Sale16.353,87363,32431,127Feb 20 12:00 AM
Cho EstherSVP, General CounselFeb 18 '26Sale16.354,74577,58139,755Feb 20 12:00 AM
Regnante KeithCHIEF FINANCIAL OFFICERFeb 18 '26Sale16.354,73977,48339,261Feb 20 12:00 AM
Pontifax Management 4 G.P. (2015) Ltd.10% OwnerOct 15 '25Sale17.75155,2622,755,9010Oct 17 12:00 AM
ADAR1 Capital Management, LLC10% OwnerOct 15 '25Sale17.75743,35813,194,6050Oct 15 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR